Dinmar Labs combines machine vision and deep learning to analyze CT and MRI scans in seconds — surfacing early signs of disease that can be missed by the human eye.
Our platform acts as a tireless second reader for radiology teams — triaging studies, highlighting suspicious regions, and quantifying change over time.
Convolutional and transformer-based vision models examine every slice of a CT or MRI volume at the voxel level, detecting subtle density and texture patterns.
Studies with suspected critical findings are moved to the top of the worklist automatically, shrinking time-to-diagnosis from days to minutes.
Trained to catch the earliest indicators of disease — small nodules, early lesions and micro-structural change — when treatment is most effective.
Automatic measurement and longitudinal comparison show how a finding has evolved across prior scans, with objective, reproducible metrics.
Our AI supports — never replaces — the radiologist. Every flag includes a visual heatmap and confidence score for transparent review.
De-identified data pipelines, encryption in transit and at rest, and deployment options that keep patient data inside hospital networks.
Founder Roger Dinmar recognized early that machine vision and machine learning could transform how disease is found in medical images. He assembled a small, dedicated team to prove the concept — and the results spoke for themselves.
Today, with our first round of funding secured and two major universities partnering on clinical trials and development, Dinmar Labs is taking that technology to the next level.
Meet Dinmar Labs →
Our multi-site trial with two university partners has passed its enrollment target. Here is what the interim data is telling us about speed and accuracy in real clinical workflows.
Read more →
A milestone for any medical AI company: independent peer review. We break down the methodology, the results and what comes next.
Read more →
We have raised our first institutional round to scale our platform, expand clinical trials and grow our teams in Baltimore and Oxford.
Read more →Whether you're an investor, a health system, or a researcher, we'd love to hear from you.
Investor Relations Early Adopter Program* Performance figures reflect internal retrospective validation studies and are provided for informational purposes. Dinmar Labs technology is investigational and not yet cleared for clinical diagnostic use.
